SCHEMBL8702001

SCHEMBL8702001

CCOc1ccc(CCc2ccccc2O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.48
FFAR4 Q5NUL3 1/20 0.48
SLC5A1 P13866 1/20 0.48
SLC5A2 P31639 1/20 0.48
GPR84 Q9NQS5 1/20 0.47
NQO1 P15559 1/20 0.47
KDM4E B2RXH2 2/20 0.47
LTA4H P09960 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 2/20 0.46
TP53 P04637 1/20 0.46
HTT P42858 1/20 0.46
MAPT P10636 2/20 0.44
HTR1A P08908 1/20 0.44
ABCB1 P08183 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15079410 0.85 CYP4F2 (0.49) NQO1KDM4ELTA4HMEN1KMT2A
SCHEMBL2580611 0.85 KEAP1 (0.59) SLC5A1SLC5A2NQO1KDM4ELTA4H
SCHEMBL8702795 0.84 ABCB1 (0.44) FFAR1FFAR4NPC1RAB9ATP53
SCHEMBL994168 0.83 ABCB1 (0.56) SLC5A1SLC5A2KDM4ELTA4HNPC1
SCHEMBL8702737 0.83 ABCB1 (0.49) TP53HTR1AABCB1
SCHEMBL15079893 0.81 ALDH1A1 (0.49) FFAR1SLC5A1SLC5A2MEN1KMT2A
SCHEMBL8702688 0.80 TAAR1 (0.50) TP53HTR1ATAAR1
SCHEMBL28616323 0.80 NQO1 (0.74) SLC5A1SLC5A2GPR84NQO1LTA4H
SCHEMBL15079368 0.79 CYP4F2 (0.47) FFAR1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL27793869 0.78 LTA4H (0.70) SLC5A1SLC5A2GPR84NQO1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0844000-A1 Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis SANKYO COMPANY LIMITED (JP) 1998-05-27 EP disclosed
US-5556864-A TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
CN-1102640-A Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory and psychiatric disorders SANKYO CO (JP) 1995-05-17 CN disclosed
EP-0600717-A1 Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis SANKYO COMPANY LIMITED (JP) 1994-06-08 EP disclosed